1.3K(top 0.1%)
papers
60.9K(top 0.1%)
citations
104(top 0.1%)
h-index
228(top 0.1%)
g-index
1.4K
all documents
66.2K
doc citations
5.4K
citing journals

Top Articles

#TitleJournalYearCitations
1PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine20157,696
2Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience20174,945
3Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialLancet, The20062,349
4Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 StudyJournal of Clinical Oncology20201,740
5Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017JAMA Oncology20191,691
6Human natural killer cellsBlood20081,572
7Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyLancet Oncology, The20201,363
8Prevalence of Oral HPV Infection in the United States, 2009-2010JAMA - Journal of the American Medical Association2012875
9Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral NeuropathyJAMA - Journal of the American Medical Association2013785
10Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019JAMA Oncology2022719
11Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal CancerJAMA - Journal of the American Medical Association2017670
12Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like CellsCancer Cell2013665
13MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancerProceedings of the National Academy of Sciences of the United States of America2011641
14Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendationsAnnals of Oncology2015607
15microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancerOncogene2011600
16The genomic landscape of hypodiploid acute lymphoblastic leukemiaNature Genetics2013588
17PTEN Mutation Spectrum and Genotype-Phenotype Correlations in Bannayan-Riley-Ruvalcaba Syndrome Suggest a Single Entity With Cowden SyndromeHuman Molecular Genetics1999562
18The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid TissuesAnnals of Oncology1999532
19MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokersProceedings of the National Academy of Sciences of the United States of America2009488
20Loss-of-Function Mutations in PPARγ Associated with Human Colon CancerMolecular Cell1999485
21Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trialLancet Oncology, The2017460
22Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineProceedings of the National Academy of Sciences of the United States of America2010443
23Aromatase Inhibitors in the Treatment of Breast CancerEndocrine Reviews2005431
24The World Cancer Research Fund/American Institute for Cancer Research Third Expert Report on Diet, Nutrition, Physical Activity, and Cancer: Impact and Future DirectionsJournal of Nutrition2020386
25Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cellsBlood2009363
26Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeuticsCell Research2015354
27Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy resultsBlood2015349
28Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the BreastAmerican Journal of Pathology1999342
29MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2)Proceedings of the National Academy of Sciences of the United States of America2010333
30Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responsesProceedings of the National Academy of Sciences of the United States of America2006328
31Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and RecommendationsBiology of Blood and Marrow Transplantation2014305
32TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology2011291
33Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian CancerJournal of Clinical Oncology2019289
34Location and cellular stages of natural killer cell developmentTrends in Immunology2013288
35Differential Nuclear and Cytoplasmic Expression of PTEN in Normal Thyroid Tissue, and Benign and Malignant Epithelial Thyroid TumorsAmerican Journal of Pathology2000283
36Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line TherapyJournal of Clinical Oncology2019274
37Clinical Relevance of Microsatellite Instability in Colorectal CancerJournal of Clinical Oncology2010273
38Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient OutcomesGastroenterology2015273
39MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon CancerCancer Cell2014267
40Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationNature Medicine2020255
41Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 studyLancet Oncology, The2015249
42RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression SignaturesJournal of Clinical Oncology2012242
43Myc Requires Distinct E2F Activities to Induce S Phase and ApoptosisMolecular Cell2001233
44CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsetsBlood2010228
45Postibrutinib outcomes in patients with mantle cell lymphomaBlood2016228
46Targeting SREBP-1-driven Lipid Metabolism to Treat CancerCurrent Pharmaceutical Design2014228
47Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer TherapyClinical Cancer Research2004225
48The Epidemiology of Arm and Hand Swelling in Premenopausal Breast Cancer SurvivorsCancer Epidemiology Biomarkers and Prevention2007224
49Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 studyLancet Oncology, The2021222
50LINE-1 Hypomethylation in Cancer Is Highly Variable and Inversely Correlated with Microsatellite InstabilityPLoS ONE2007221